Drug intelligence / Profile preview

MDH-114

Development stage: Unknown
Lead developer: MD Healthcare
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

MDH-114 is a microbial extracellular vesicle (EV) nanotherapeutic developed by MD Healthcare for the treatment of central nervous system (CNS) disorders, including Alzheimer's disease, epilepsy, and autism spectrum disorder (ASD). The drug is based on a proprietary platform that utilizes the communication axis between the microbiome and the host via extracellular vesicles. These EVs are designed to cross the blood-brain barrier and modulate pathways involved in neuroinflammation and neurodegeneration. According to company pipeline data, MDH-114 completed pharmacology studies and progressed through toxicology and CMC (Chemistry, Manufacturing, and Controls) stages in late 2023, with Phase 1 clinical trials scheduled to commence in the fourth quarter of 2024.

Beyond the preview

Go deeper on MDH-114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDH-114.

Explore the full profile